A multinational pharmaceutical company had a vaccine in phase III trials which, if successful, might reduce the chance of becoming infected by HIV or might reduce the severity of the disease if infection did take happen. Hyderus helped them understand whether there would be a market for a vaccine which would not prevent most new infections but could, nonetheless, reduce the severity of the epidemic significantly. Our research in 27 countries suggested that there would be a limited demand. Our work also showed that HIV was a falling priority for governments even in the worst affected countries of Southern Africa. This project was a partnership with our sister company, Baird’s CMC.